Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Trending in China: Can Music Streamers Help Users’ Depression?
Core Parts of China’s Beidou Satellite System ‘100% Made in China’
Trending in China: Xiaomi CEO’s Shows How Best To Harness China’s Social Media Humor for Serious Business
Apple Takes Down Over 30,000 Apps from China Store Amid Government Crackdown
Chinese Chipmaker SMIC to Establish Joint Venture for Wafer Production
Microsoft Said Plan to Acquire TikTok Will Continue
Uber Abandons Plan to Move Regional Headquarters to Hong Kong
Trending in China: Undergraduate Degree in Housekeeping — Valuable Asset or Waste of Resources?
Huawei and Apple Shine in China’s Smartphone Market During Second Quarter
Video Streamer iQiyi Eyeing Southeast Asian, Middle East Expansion, Executive Says
Lawson Expands in China With Prefab Convenience Stores
TikTok Undergoing U.S. Investment Review, Treasury Secretary Says
Chinese Community E-commerce Firm Nice Tuan Nets $80 Million in Third Funding in 2020
Trending in China: Shanghai Film Festival Rekindles Childhood Memories with Outdoor Screenings
China’s EHang Gets Green Light to Test Self-Flying Vehicles in Quebec
Trending in China: Pop Star Jay Chou’s Livestream Signals Kuaishou’s Increasing Partnership with Celebrities
Tencent to Pick Up Stake in Shanghai-listed Weaver Network for $110 Million
U.S. Senators Worry TikTok Could Be Used to Interfere in Elections
Tesla Launches Hiring Spree in China as It Prepares for Shanghai Production of Model Y
ByteDance AI Lab Head to Leave as TikTok Faces Global Headwinds
Hillhouse-Backed Genor Plans $200 Million Hong Kong IPO

By Bloomberg / Dec 13, 2019 04:36 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Genor Biopharma Co. is planning an initial public offering in Hong Kong that could raise about $200 million, according to people familiar with the matter.

The company, backed by affiliates of private equity firm Hillhouse Capital, has contacted potential advisers for the share sale, said the people, who asked not to be identified as the discussions are private. The listing could happen as soon as mid-2020, the people said.

The Shanghai-based company was seeking to raise about $100 million from private investors earlier this year to fuel growth, Bloomberg News reported in October. The Chinese drugmaker’s valuation could reach as much as $1 billion after the funding round, people familiar with the matter have said.

Details of the IPO including size and timeline could still change as deliberations continue, the people said. A representative for Genor didn’t immediately respond to requests for comment.

Founded in 2007, Genor is developing and commercializing therapeutic antibodies to fight cancer and other diseases, according to its website. It has more than 400 employees in three cities in China as well as its laboratory in the U.S. The drugmaker has more than 10 products in its pipeline with many of them in clinical development.

Share this article
Open WeChat and scan the QR code